Share This Page
Sulfacytine - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for sulfacytine and what is the scope of patent protection?
Sulfacytine
is the generic ingredient in one branded drug marketed by Glenwood and is included in one NDA. Additional information is available in the individual branded drug profile pages.Summary for sulfacytine
| US Patents: | 0 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 40 |
| Patent Applications: | 2,936 |
| DailyMed Link: | sulfacytine at DailyMed |
US Patents and Regulatory Information for sulfacytine
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glenwood | RENOQUID | sulfacytine | TABLET;ORAL | 017569-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Sulfacytine Market Analysis and Financial Projection Experimental
Market Dynamics and Financial Trajectory for Sulfadiazine
Introduction
Sulfadiazine, a member of the sulfonamide class of antibiotics, is widely used to treat various bacterial infections. Understanding the market dynamics and financial trajectory of this drug is crucial for pharmaceutical companies, investors, and healthcare professionals.
Market Overview
Pharmaceutical Sector Dependence
The market activities of sulfadiazine are closely tied to the performance of the pharmaceutical sector. In regions like India, government policies have played a significant role in boosting production activities and imports, which in turn affect the sulfadiazine market[1].
Global Demand and Supply
The demand for sulfadiazine is driven by its versatility in treating bacterial infections, including its use in oral, topical, vaginal, and ophthalmic therapies. However, the supply chain is heavily dependent on the import of raw materials, which introduces uncertainties in the price trend due to fluctuations in global raw material costs[1].
Price Trends
Impact of Raw Materials
The cost of producing sulfadiazine has been influenced by the rise in crude oil prices, which affects the overall production costs. This trend was particularly evident in the third and fourth quarters, where raw material costs maintained a positive momentum[1].
Market Sentiments
Despite the uncertainties, general market sentiments for sulfadiazine have been largely positive. Analysts anticipate stable supply and demand dynamics, suggesting minimal changes in the market going forward[1].
Growth Drivers
Rising Burn Injuries
One of the key growth drivers for the related compound, silver sulfadiazine, is the increasing number of burn injuries globally. This trend is expected to fuel the demand for anti-burn lotions and creams, which in turn could contribute to the growth of the sulfadiazine market[3][5].
Advancements in Products
Advancements in existing products and the development of new formulations are expected to fuel the demand for sulfadiazine. These innovations could propel the market forward by offering more effective and user-friendly treatments[3][5].
Regional Market Analysis
North America
North America is anticipated to be a dominant region in the sulfadiazine market due to the high demand for wound care products in countries like the US and Canada. The well-developed healthcare infrastructure in these countries further supports market growth[5].
Europe
Europe is expected to witness significant growth, driven by increased awareness of silver sulfadiazine in countries such as the UK and Germany. Government initiatives and funding for market players are also expected to bolster growth in this region[3][5].
Asia Pacific
The Asia Pacific region is projected to experience strong growth due to the rapidly developing healthcare infrastructure and the growing medical tourism industry in countries like India. This region is likely to be a key market for sulfadiazine in the coming years[3][5].
Latin America and Middle East & Africa
These regions are anticipated to witness sluggish growth due to the lack of presence of leading market players. However, there is potential for growth if smaller players can secure funding from private investors to support their research and development efforts[3][5].
Financial Trajectory
Production Costs
The financial trajectory of sulfadiazine is significantly influenced by production costs, which have been on the rise due to increased raw material costs. This trend is expected to continue, affecting the profitability of manufacturers[1].
Generic Drug Dynamics
In the generic drug market, the entry of multiple competitors can drive down prices. However, generic drug prices remain above long-run marginal costs until there are eight or more competitors. This dynamic can impact the financial performance of companies producing sulfadiazine, especially if they face increased competition[4].
Revenue and Profits
The revenue and profits from sulfadiazine sales are expected to grow, driven by increasing demand and advancements in product formulations. However, the flow of profits may decrease as more competitors enter the market, leading to reduced price-cost margins[4].
Challenges and Opportunities
Antimicrobial Resistance
One of the significant challenges facing the sulfadiazine market is antimicrobial resistance. The development of new antibiotics is hindered by low risk-adjusted net present value (rNPV) compared to other therapeutic categories, which can discourage pharmaceutical companies from investing in R&D for new antimicrobials[2].
Government Initiatives
Government initiatives and funding can provide significant opportunities for market growth. Funding for leading market players can support research and development, helping smaller players to expand their market presence and increase their revenue shares[3][5].
Competitive Landscape
Key Players
The global sulfadiazine market is highly competitive, with prominent players such as 3M Company, Baxter International Inc., Johnson and Johnson Ltd., and Monarch Pharmaceuticals. These companies have established themselves through consistent performance and are expected to continue dominating the market[5].
Growth Strategies
Leading market players are expected to gain a competitive edge through novel product launches and collaborations with smaller players. These strategies can help in expanding market presence and increasing revenue shares[5].
Key Takeaways
- Market Dependence: The sulfadiazine market is closely tied to the pharmaceutical sector and global raw material costs.
- Growth Drivers: Rising burn injuries and product advancements are key drivers.
- Regional Growth: North America, Europe, and Asia Pacific are expected to be significant markets.
- Financial Trajectory: Production costs and competition dynamics will influence profitability.
- Challenges: Antimicrobial resistance and low rNPV for new antibiotics are significant challenges.
- Opportunities: Government initiatives and funding can support market growth.
FAQs
What are the primary uses of sulfadiazine?
Sulfadiazine is used to treat various bacterial infections and can be administered orally, topically, vaginally, or ophthalmically. It is also used in combination with other drugs to treat conditions like toxoplasmosis[1][3].
How does the cost of raw materials affect the sulfadiazine market?
The cost of raw materials, particularly the rise in crude oil prices, directly impacts the production costs of sulfadiazine, introducing uncertainties in the price trend[1].
What are the key growth drivers for the silver sulfadiazine market?
The rising number of burn injuries and increasing cases of morbidity due to non-fatal burns are key growth drivers. Advancements in product formulations also contribute to market growth[3][5].
How does competition affect the generic drug market for sulfadiazine?
In the generic drug market, increased competition drives down prices, but prices remain above long-run marginal costs until there are eight or more competitors. This dynamic affects the financial performance of companies producing sulfadiazine[4].
What challenges does the development of new antibiotics face?
The development of new antibiotics faces challenges such as low risk-adjusted net present value (rNPV) compared to other therapeutic categories, high registration costs, and the risk of antimicrobial resistance[2].
Sources
- Procurement Resource: Sulfadiazine Price Trend, Index, News, Chart, Database.
- Access to Medicine Foundation: Antimicrobial Resistance Benchmark 2018.
- BioSpace: Silver Sulfadiazine Market: Rising number of burn injuries across the world to drive the market.
- Federal Trade Commission: Generic Drug Industry Dynamics.
- Transparency Market Research: Silver Sulfadiazine Market Insight and Trends 2031.
More… ↓
